Aurinia Pharmaceuticals Inc. - 10-Q Summary (Q1 2026)
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on autoimmune diseases, primarily commercializing LUPKYNIS (voclosporin) for lupus nephritis. The company is also developing aritinercept. As of May 6, 2026, there were 128.6 million common shares outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $77.7 million | $62.5 million |
| Net Product Sales | $73.6 million | $60.0 million |
| Net Income | $34.4 million | $23.3 million |
| Diluted EPS | $0.25 | $0.16 |
| Operating Cash Flow | $32.6 million | $1.3 million |
| Cash & Investments | $378.8 million | $398.0 million (Dec 31, 2025) |
| Gross Margin | 92% | 86% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 24% year-over-year, driven by a 23% increase in net product sales of LUPKYNIS due to market penetration and a 64% increase in collaboration revenue from manufacturing services provided to partner Otsuka.
- Profitability: Net income rose 47% to $34.4 million. Operating income increased to $41.4 million from $21.8 million.
- Expense Management: Cost of revenue decreased 24% to $6.5 million, improving gross margin. Restructuring costs present in Q1 2025 ($1.5 million) were absent in Q1 2026. However, R&D expenses increased 30% to $7.5 million due to personnel costs and clinical supply.
- Tax Impact: Income tax expense increased significantly to $9.6 million (from $1.0 million) due to the release of a valuation allowance on deferred tax assets, as the company now expects to realize these benefits.
- Share Repurchases: The company repurchased 2.5 million shares for $36.8 million during the quarter.
Outlook, Risks, and Unusual Items
- Merger Activity: On March 30, 2026, Aurinia entered a definitive agreement to acquire Kezar Life Sciences, Inc. for $6.955 per share in cash plus a contingent value right (CVR). The transaction is expected to close in Q2 2026.
- Leadership Transition: Effective March 2026, the company underwent a complete executive leadership change. Kevin Tang was appointed CEO, replacing Peter Greenleaf. New COO and CFO were also appointed. Former officers received severance packages.
- Liquidity: Management expects to fund future operations with existing cash and operating cash flows. The company maintains a strong liquidity position with $378.8 million in cash and investments.
- Risks: Risks include the success of the Kezar merger, commercialization of LUPKYNIS, and the ability to control expenses. No material changes to risk factors were reported outside of the merger and leadership changes.
Investor Verification Checklist
- Verify the closing conditions and timeline for the Kezar Life Sciences acquisition and the specific terms of the Contingent Value Right (CVR).
- Confirm the impact of the executive leadership transition on strategic execution and the specific costs associated with severance packages.
- Monitor the sustainability of the 92% gross margin as sales volumes increase and manufacturing costs evolve.
- Review the share repurchase program status; approximately $125.3 million remains available under the current plan as of March 31, 2026.
- Assess the realization of deferred tax assets now that the valuation allowance has been released, ensuring future tax provisions remain accurate.